The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon


Work +49 89 35 06 50

Show all Pressemitteilungen

BEITEN BURKHARDT berät die dormakaba Gruppe bei Anleiheemission über CHF 680 Mio.

January 2018

München, 21. Dezember 2017 – Die internationale Wirtschaftskanzlei BEITEN BURKHARDT hat die dormakaba Gruppe bei der Emission von zwei Anleihen mit einem Gesamtvolumen von CHF 680 Mio. als Doppeltranchen am Schweizer Kapitalmarkt zu Fragen des deutschen Rechts im Zusammenhang mit der Besicherung durch eine deutsche Konzerngesellschaft beraten. Emittent der Anleihen mit einer Laufzeit von vier Jahren, einem Coupon von 0,375 Prozent und einem Emissionspreis von 100,298 Prozent sowie mit einer Laufzeit von acht Jahren, einem Coupon von 1,00 Prozent und einem Emissionspreis von 100,46 Prozent ist die dormakaba Finance AG, sie werden von der börsennotierten Obergesellschaft dormakaba Holding AG garantiert und mit einer konzerninternen Upstream-Garantie der deutschen Zwischenholding dormakaba Holding GmbH & Co. KGaA unterlegt.

Die Emission per Valuta 13. Oktober 2017 erfolgte unter Federführung der UBS Investment Bank (Sole Bookrunner) und unter Mitwirkung der Zürcher Kantonalbank (Joint-Lead Manager) sowie der Deutsche Bank AG London Branch, acting through Deutsche Bank AG Zurich Branch als Senior Co-Manager und der Commerzbank als Co-Manager.

Die dormakaba Gruppe ist eines der Top-3-Unternehmen im Weltmarkt für Zutritts- und Sicherheitslösungen und bietet Produkte, Lösungen und Services rund um den sicheren Zutritt zu Gebäuden und Räumen aus einer Hand.

Berater dormakaba Gruppe:

BEITEN BURKHARDT: Die Partner Michael Ziegler, LL.M. (UPenn) und Petra Fendt (beide Federführung), Dr. Dirk Tuttlies (alle Bank-/Finanz- und Kapitalmarktrecht), Of Counsel Dr. Jack Schiffer und Partnerin Insa Cornelia Müller (beide Corporate/M&A) sowie Partner Dr. Michael Hils (Steuern, alle München).

Zu allen Fragen des Schweizer Rechts berieten der Partner Hansjürg Appenzeller und Mitarbeiter Daniel Hulmann (beide Banken- und Finanzmarktrecht) von Homburger AG.

Die beteiligten Syndikatsbanken haben die Emission jeweils inhouse begleitet.


Michael Ziegler, LL.M.
Tel.: +49 89 350 65 – 1441

Petra Fendt
Tel.: +49 89 350 65 – 1441

Presse & Öffentlichkeitsarbeit:

Frauke Reuther
Tel.: +49 69 75 60 95 – 570

Informationen zu BEITEN BURKHARDT

  • BEITEN BURKHARDT ist eine unabhängige internationale Wirtschaftskanzlei mit einem fokussierten Beratungsangebot und rund 290 Anwälten an acht Standorten.
  • Mit unserer langjährigen Präsenz in Deutschland, Brüssel, China und Russland beraten wir den Mittelstand, Großunternehmen und Konzerne unterschiedlichster Wirtschaftszweige sowie Banken und die öffentliche Hand.

Co-Publishing weltweit

Rechtsentwicklungen und Neuigkeiten der führenden Anwälte in verschiedenen Jurisdiktionen. Für Beitrüge schicken Sie bitte eine Anfrage per Email an
  • China Drug Registration Regulation - Public consultation on amendment closes - March 2014

    In February 2014, the China Food and Drug Administration (“CFDA”) invited second-round comments from the public regarding proposed amendments to the China Drug Registration Regulations (“DRR”). One of the proposed amendments touches upon patent protection for drugs in China.
  • Revised NDRC Measures for Approval and Filing of Outbound Investment Projects - April 2014

    The National Development and Reform Commission ( NDRC ) released a new set of Management Measures for Approval and Filing of Outbound Investment Projects ( 境外投资项目核准和备案管理办法) ( New Measures ) on 8 April 2014. The New Measures take effect on 8 May 2014 and will replace the Interim Management Measures for Approval of Outbound Investment Projects ( 境外投资项目核准暂行管理办法) ( Original Measures ) which have been in force since 9 October 2004.
  • Insurance Update - CIRC Issues Insurance M&A Measures: What are the impacts and applications?

    On 21 March 2014, CIRC issued the Administrative Measures on the Acquisition and Merger of Insurance Companies (the Insurance M&A Measures ) which will take effect from 1 June 2014. The Insurance M&A Measures apply to M&A activities whereby an insurance company is the target for a merger or acquisition. The target insurance company could be either a domestic or a foreign invested insurer. However, the Insurance M&A Measures will not apply to any equity investment by insurance companies in non-insurance companies in China or in overseas insurance companies.
  • China issues new rules to regulate medical devices - May 2014

    The Regulations on Supervision and Administration of Medical Devices (in Chinese《医疗器械监督管理条例》, State Council Order No. 650) (the Medical Device Regulations) were amended by China's State Council on 31 March 2014 and will come into effect on 1 June 2014. This is the first amendment in more than a decade since the Medical Device Regulations were first promulgated in 2000, even though the amendment was initiated eight years ago in 2006. The 2014 amendment unveils reforms on the regulatory regime for medical devices market in China from various aspects.
  • Hong Kong: The evolving role of independent non-executive directors - May 2014

     In a recent speech given by Mr. Carlson Tong, Chairman of the Securities and Futures Commission, Mr. Tong pointed out that companies can improve corporate governance by attaching higher importance to the role of their board of directors as an internal gatekeeper. Mr. Tong said that this can be done more easily by having effective independent non-executive directors (INEDs) on the board.
  • Walking a fine line in China:Distinguishing between legitimate commercial deals and commercial bribe

    China in the 21st century exemplifies an atmosphere of great opportunity and intense competition. Against this backdrop, it has become increasingly common for businesses to adopt a variety of practices in order to make their products and services competitive. Such practices may include paying middle-men to promote sales and giving incentives to buyers directly. However, whilst revenue spikes are undoubtedly welcome, businesses should bear in mind the potential backlash arising out of these commercial arrangements. The risk that such arrangements may not comply with anti-bribery and corruption laws and therefore cause business significant damage in the long term should not be underestimated.
  • Competition law developments in East Asia - May 2014

    Authorities in Hong Kong have taken further steps in their deliberate approach to enforcing the Competition Ordinance. A little over a year after it was appointed, the Competition Commission released a report in which it provides a brief introduction to the Ordinance as well as a roadmap leading to its full entry into force. The report also explains how the Commission will prioritise its enforcement activities, and identifies the guidelines, policies and compliance tools which it plans to release before the Ordinance is enforced. Currently only some of the institutional provisions of the Ordinance are effective, allowing the Commission and the Competition Tribunal to prepare for enforcement.
  • Rise of the private healthcare sector - July 2014

    As of 2013, China had 9,800 private hospitals, representing almost half of the total number of hospitals in the country 1 . However, private hospitals still severely lag behind their public peers due to low utilisation, talent shortages and incomplete social insurance coverage. As part of China's ongoing healthcare reform initiatives, the Chinese government has set a goal to increase the share of patients treated by private hospitals to 20% by the end of 2015 2 .
  • Walking a Tightrope in Singapore - July 2014

    The world has no borders and distance is negligible for the technologically savvy criminal. Individuals with illicit funds to launder or terrorist activities to finance can, with the latest technology, transfer high volumes of money around the globe almost instantaneously and seek to conceal the origin or the destination of the funds.
  • Indonesia banking bill: proposed restrictions on foreign investment - July 2014

    Indonesia's House of Representatives is currently considering a new draft banking bill (the Banking Bill ) which, if passed into law in its current form, will: